Drugs / UA026
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07038720 | May 2025 → Mar 2026 overdue | psoriasis | Usynova Pharmaceuticals Ltd. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UA026 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07038720 ↗ |
| Action | Inhibit | “UA026 is a high potency small molecule IL-17A inhibitor.” NCT07038720 ↗ |
| Modality | Small molecule | “UA026 is a high potency small molecule IL-17A inhibitor.” NCT07038720 ↗ |
| Route | Oral | “single or multiple oral doses of the UA026” NCT07038720 ↗ |
| Target | IL17A | “UA026 is a high potency small molecule IL-17A inhibitor.” NCT07038720 ↗ |